Baseline characteristics
| Characteristic . | Value . |
|---|---|
| Patients, n (%) | 33 (100) |
| Male sex, n (%) | 28 (85) |
| Median age, y (range) | 42 (9-61) |
| ECOG performance status 2-4, n (%) | 13 (39) |
| Stage III/IV, n (%) | 4/23 (82) |
| LDH level greater than normal, n (%) | 20 (61) |
| At least 2 extranodal sites, n (%) | 16 (48) |
| CNS involvement, n (%) | 4 (12) |
| Age-adjusted IPI | |
| 0/1, n (%) | 4/4 (24) |
| 2/3, n (%) | 17/8 (76) |
| Median CD4 count, cells/μL (cells/mm3) | 208 |
| 3-100 cells/μL (3-100 cells/mm3), n (%) | 14 (42) |
| 101-674 cells/μL (101-674 cells/mm3), n (%) | 29 (58) |
| HIV viral load | |
| Median | 36 100 |
| Range | 0-6 080 000 |
| cART history | |
| cART naive, n (%) | 9 (27) |
| Prior cART, n (%) | 24 (73) |
| Histologic subtype (n = 29) | |
| GCB, n (%) | 21 (72) |
| Non-GCB, n (%) | 8 (28) |
| EBV (n = 29) | |
| Positive, n (%) | 9 (31) |
| Negative, n (%) | 20 (69) |
| Characteristic . | Value . |
|---|---|
| Patients, n (%) | 33 (100) |
| Male sex, n (%) | 28 (85) |
| Median age, y (range) | 42 (9-61) |
| ECOG performance status 2-4, n (%) | 13 (39) |
| Stage III/IV, n (%) | 4/23 (82) |
| LDH level greater than normal, n (%) | 20 (61) |
| At least 2 extranodal sites, n (%) | 16 (48) |
| CNS involvement, n (%) | 4 (12) |
| Age-adjusted IPI | |
| 0/1, n (%) | 4/4 (24) |
| 2/3, n (%) | 17/8 (76) |
| Median CD4 count, cells/μL (cells/mm3) | 208 |
| 3-100 cells/μL (3-100 cells/mm3), n (%) | 14 (42) |
| 101-674 cells/μL (101-674 cells/mm3), n (%) | 29 (58) |
| HIV viral load | |
| Median | 36 100 |
| Range | 0-6 080 000 |
| cART history | |
| cART naive, n (%) | 9 (27) |
| Prior cART, n (%) | 24 (73) |
| Histologic subtype (n = 29) | |
| GCB, n (%) | 21 (72) |
| Non-GCB, n (%) | 8 (28) |
| EBV (n = 29) | |
| Positive, n (%) | 9 (31) |
| Negative, n (%) | 20 (69) |
ECOG indicates Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; CNS, central nervous system; IPI, International Prognostic Index; cART, combination antiretroviral therapy; GCB, germinal center B-cell; and EBV, Epstein-Barr virus.